Press release
Viral Conjunctivitis Drugs Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2017-2025
Viral conjunctivitis is an inflammation of the conjunctiva, which is a thin outermost layer of the sclera and inner layer of eyelid. Viral conjunctiva is caused due to infections from virus such as adenovirus, herpes simplex virus, varicella zoster virus, picornavirus, poxvirus, and human immunodeficiency virus. It is also called as Pinkeye disease. Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific.Treatment can include artificial tear drops to lower the dryness and irritation from infection, vasoconstrictors to reduce eye redness, decongestants to reduce the swelling, and antihistamines to reduce itching. Treatments usually are continued for one to two weeks, depending on the severity of the infection. Anti-viral therapy is utilized to treat infections from herpes simplex and varicella zoster virus.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1281
New drugs development in the U.S. to propel growth of the viral conjunctivitis market
According to study published in the journal Ophthalmology in December 2017, approximately 80% of conjunctivitis cases in the U.S. are associated with viral conjunctivitis. According to study published in Review of Ophthalmology in January 2017, around 15 per 1000 population in the U.S. suffer from viral conjunctivitis. As per a study in Review of Optometry in 2016, an estimated 20,000 new cases, 48,000 cases of recurrences, and prevalence of 4,00,000 cases of herpes simplex keratitis were reported every year in U.S. Considering this facts, U.S. is expected to dominate the viral conjunctivitis drugs market. Also, increasing investment for development of new drugs to treat the viral conjunctivitis are further expected to propel the viral conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the phase 2 clinical studies in 2016. There is also increased awareness amongst patients about approaching the ophthalmologist to treat viral conjunctivitis.
However, there is no direct anti-viral treatment available yet for conjunctivitis, which if available may open new opportunity in viral conjunctivitis drugs market. To treat viral conjunctivitis often it becomes difficult to clinically differentiate the viral conjunctivitis from the bacterial conjunctivitis which leads to miss diagnosis. Many physicians at primary care centers prescribe antibiotic to treat viral conjunctivitis due to miss diagnosis and this chain of events limits the expansion of viral conjunctivitis drugs market. According to 2017 study in Ophthalmology, an estimated 83% patients of acute conjunctivitis visited primary care centers instead of ophthalmologist, which leads to overlap of diagnosis and treatment of viral conjunctivitis in turn restraining market growth.
Viral Conjunctivitis Drugs Market Taxonomy
On the basis of drug class:
Artificial tears
Decongestants
Anti-histaminic
NSAIDS
Anti-Viral drugs
On the basis of the distribution channel:
Hospital Pharmacy
Retail Pharmacy
Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, and Quidel Corporation. Market players are investing in research to development of novel therapies to treat viral conjunctivitis.
Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/viral-conjunctivitis-drugs-market-1281
NiCox S.A. in March 2017, received the FDA approval for its ZERVIATE1 (cetirizine ophthalmic solution 0.24%) as New Drug Application (NDA), which is the first antihistaminic topical ocular formulation for the treatment of itching due to allergic conjunctivitis. Company is looking to commercialize the product in the U.S. through partnership. In 2015, Shire plc announced acquisition of Foresight Biotherapeutics for US$ 300 million. Foresight Biotherapeutics has experimental eye drop FST-100 in its pipeline, which is a combination of 0.6% povidone iodine and 0.1% dexamethasone to treat both viral and bacterial conjunctivitis. This acquisition would add growth to Shire plc’s ophthalmic portfolio.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Viral Conjunctivitis Drugs Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2017-2025 here
News-ID: 947084 • Views: 385
More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the…

Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic…

Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth
Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to…

Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the…
More Releases for Viral
Viral Inactivation Market Growing Demand of Kits and Reagents Viral Inactivation …
According to Precision Business Insights (PBI), the latest report, the Viral Inactivation market is expected to be worth USD 2.1 billion in 2022, growing at a 12.8% CAGR from 2022 to 2028. The primary driver of the expansion of the global Viral Inactivation market are speedy growth in pharmaceutical and biotechnology industries and strong inclination of R&D investments in life sciences industry.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/viral-inactivation-market/
Kits &…
Global Anti-Viral Drug Therapy Market | Global Anti-Viral Drug Therapy Industry …
Anti-viral drug therapy market comprises of sales of branded & generic anti-viral drugs and related services by entities that manufacture the branded or generic anti-viral drugs for treating microbial infections. Anti-viral drug therapy industry includes several establishments that manufacture anti-viral drugs, which are used to treat diseases caused by viral infections. Examples of antiviral drugs include cidofovir, amantadine, zanamivir, idoxuridine, famiciclovir, tenofovir, adefovir and ribavirin.
According to study, “Anti-Viral Drug Therapy…
Viral Antigens Market to Reap Excessive Revenues by 2028(Based on product type, …
Antigens are commonly referred to as substances that are capable of triggering an immune response in a host by activating the lymphocytes or initiating antibody production against infections. Depending upon the fact that they either enter the human body or originate within the body, viral antigens are classified as foreign or self-antigens respectively. Among these, self-antigens comprise mutated or overexpressed proteins. However, foreign antigens are likely to include bacteria, parasites,…
Viral Vector and Plasmid DNA Manufacturing Market - Increase In Awareness Regard …
The Viral Vector and Plasmid DNA Manufacturing Market is expected to reach $ 1,090 million in 2023, growing at an annual average rate of 22.6% from 2017 to 2023. North America was the largest contributor to the viral vector and plasmid DNA markets in 2016. However, the Asia Pacific region is expected to have the highest growth rate during the forecast period.
Gene therapy has included tools such as viral vectors…
Viral Vaccines Market : Challenges and Opportunities Against Viral Diseases
Vaccines are biotic compositions. They are basically formulated from living beings that increase the resistance against a specific illness. Vaccinations that help in avoiding the occurrence of specific diseases are known as prophylactic vaccines and in other instance, the vaccines that are helpful in treating the disease are called therapeutic vaccines. A vaccine is generally produced by using a weakened or murdered type of the sickness causing microorganism. The agent…
Global Viral Molecular Diagnostics Market
The Viral Molecular Diagnostics Market reportprovides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Molecular diagnostics refers to a technique used to detect and identify the presence of genetic material or proteins associated with a specific health condition or disease. Viral molecular diagnostic helps in…